Pharming Group NV and Swedish Orphan Biovitrum announced that the European Commission has granted Pharming Marketing Authorization for its lead product Ruconest(TM) for the treatment of acute attacks of Hereditary Angioedema (HAE). Pharming will now receive a €5 million milestone payment from marke more
To use all functions of this page, please activate cookies in your browser.
